Osimertinib – a third generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) – has shown highly significant efficacy in non-small-cell lung cancer (NSCLC) patients with sensitive mutations as well as in patients with a T790M resistance mutation. EGFR T790M is a robust biomarker for the efficacy of osimertinib. Still, in a number of patients with NSCLC who harbour the EGFR T790M mutation, clinical efficacy remains very limited, which suggests primary resistance.
Jang et al. aimed to discover clinical predictive factors for the efficacy of osimertinib, and analysed patients with stage IV, EGFR T790M+ lung adenocarcinoma who were given osimertinib as salvage treatment in a retrospective study . Various baseline clinical factors were investigated according to favourable or unfavourable osimertinib efficacy group. Unfavourable efficacy (primary resistance) was defined as progression-free survival (PFS) <6 months wi...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Use of clinical registries in phase 4 of DMT Next Article
First-line Pembrolizumab Monotherapy Offers Durable OS Benefit Vs Chemotherapy in NSCLC Patients with High PD-L1 Expression »
Table of Contents: WCLC 2019
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Other Thoracic Malignancies
Phase 3 Trial Updates
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.